Remote and non-invasive opioid use screening to lower barriers to substance use disorder diagnosis and treatment
Ended Project Grant Awarded Last action
- Award ID
- R43DA061400
- Recipient
-
Tenvos Inc. UEI CXCPXF7ARM26
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $586,340
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Substance use disorder (SUD) diagnosis and treatment requires laboratory drug testing, which inflicts monetary, time, and interpersonal barriers to professional care. To date, there are no remote, non-invasive and instant opioid testing options available, limiting the potential for clinical outreach. Tenvos' solution is an artificial intelligence based technology that detects opioid use from 15 seconds of speech. Tenvos allows clinicians to screen for opioid use remotely, mitigating the barriers to clinical intervention, streamlining the clinical workflows, reducing costs, and improving the overall quality of patient care. Tenvos' solution is an easily-deployable API-first product, allowing for seamless integration into various workflows- integration with virtual health platforms, phone appointments, or large scale automatic phone-based screening campaigns. This new approach will increase access for rural and low-income populations as well as incarcerated individuals. This project aims to further develop tenvos' solution and the understanding of opioids' effects on voice production, while comparing the detection solution to current gold standard tests. The specific aims for the project's phase I set of activities include: aim 1: collecting clinical data from patients before and after the opioid treatment. Aim 2: identifying 10 vocal characteristics that are affected by opioid use and ranked from most affected to least affected. Aim 3: determining the accuracy of the machine learning model trained on this data measured by sensitivity and specificity and 95% CI. This project will achieve the aforementioned aims through a multisite observational study at doctors medical center and loma linda university health. Selected patients in the sites' emergency departments will provide voice samples prior to and following opioid administration. This data collection will allow for vocal analysis to identify characteristic differences between the voice samples taken before opioid administration and those taken after. Furthermore, this sample collection will provide the initial feasibility data to facilitate the necessary steps toward commercialization.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $293,170 | |
| Original award | $293,170 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Loma Linda University | $96,743 |
Quick answers
Who received award R43DA061400?
R43DA061400 was awarded to Tenvos Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 15, 2024.
How much is award R43DA061400 worth?
$586,340 has been obligated on R43DA061400.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award